The questions I keep beside NAD+, MOTS-c and epitalon
Some questions stay unanswered because the research hasn’t got there yet. That can be frustrating when a claim sounds very sure of itself. Here’s how I sort through the practical questions about NAD+, MOTS-c and epitalon without turning the gaps into a personal routine.
Is NAD+ actually a peptide?
No. NAD+ is a coenzyme, a helper molecule for enzymes; peptides are chains of amino acids. NMN and NR are ingredients the body can turn into NAD+. The human trial evidence concerns the ingredients and preparations tested, so a result about one can’t simply stand in for another.
Does a better test result mean a longer life?
Not on its own. It shows that a measurement changed, which may be worth investigating. To show a longer life, researchers need evidence about that outcome. The findings discussed in this guide haven’t established that these treatments extend human life, however appealing the possibility sounds.
Did MOTS-c work like exercise in people?
The exercise paper found an increase in people’s own MOTS-c after exercise. The performance results from giving MOTS-c came from mice. Calling it an exercise mimetic means it may copy aspects of exercise; it doesn’t show that taking it improves human fitness or replaces exercise.
Can I turn the studies into a personal schedule?
Animal experiments and cell studies don’t establish a safe human treatment schedule for MOTS-c or epitalon. Neither has an FDA-approved label to follow. A prescriber has to consider the person and whether treatment is appropriate at all; converting an animal amount doesn’t answer those questions.
Does a withdrawn nomination mean FDA approval?
No. The FDA page current as of April 22, 2026 lists MOTS-c and epitalon among substances whose nominations were withdrawn: the requests for FDA consideration were taken back. Their safety concerns remain listed. Withdrawal doesn’t clear them for compounding or establish safety, and compounded medicines aren’t FDA-approved.
Was the older longevity report about epitalon?
The human longevity report used Epithalamin, a gland extract. It didn’t test synthetic epitalon, and its methods leave important uncertainty about the reported results. I’d check the ingredient before leaning on the finding. Evidence about the extract doesn’t become evidence about the peptide because their names look alike.
For a clinical conversation, I’d bring one question: what evidence supports this particular claim for someone like me? A limited answer is useful, too. It helps separate a result worth following from a treatment decision the research can’t yet settle.